Abstract | BACKGROUND: METHODS: C57BL/6 male mice were fed high-fat diet for 8 weeks until development of obesity, and then injected with 50 mg/kg silibinin intraperitoneally twice per week, or vehicle for 8 weeks. Throughout the experiment, mice were continuously checked for body weight and food intake, and glucose tolerance test was performed toward the end of the experiment. Animals were sacrificed and serum and tissues were collected for biochemical, histological, and gene expression analysis to assess silibinin effects on adipose inflammation, fat accumulation, liver adipogenesis and glucose homeostasis. RESULTS: CONCLUSION: In this study, we demonstrated that silibinin as an anti-inflammatory therapy is a potential alternative to manage obesity, as well as its related complications. Moreover, silibinin-based therapies could further evolve as a novel treatment to manage various inflammation-driven disorders.
|
Authors | Mohammad Alsaggar, Shifa Bdour, Qutaibah Ababneh, Tamam El-Elimat, Nidal Qinna, Karem H Alzoubi |
Journal | BMC pharmacology & toxicology
(BMC Pharmacol Toxicol)
Vol. 21
Issue 1
Pg. 8
(01 23 2020)
ISSN: 2050-6511 [Electronic] England |
PMID | 31973745
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Inflammatory Agents
- Anti-Obesity Agents
- Silybin
- Glucose
|
Topics |
- Adipocytes
(drug effects, metabolism, pathology)
- Adipose Tissue
(drug effects)
- Animals
- Anti-Inflammatory Agents
(therapeutic use)
- Anti-Obesity Agents
(therapeutic use)
- Body Weight
(drug effects)
- Diet, High-Fat
- Disease Models, Animal
- Gene Expression
(drug effects)
- Glucose
(metabolism)
- Hypertrophy
- Liver
(drug effects)
- Male
- Mice, Inbred C57BL
- Obesity
(complications, drug therapy, pathology)
- Silybin
(therapeutic use)
|